🔥🐔 BizChicken 🐔🔥
Companies Similar to GlycoMimetics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Allakos Inc.
lirentelimab (AK002)
Allakos Inc. is a clinical stage biopharmaceutical company that develops therapeutics targeting immunomodulatory receptors on immune cells for allergy, inflammatory, and proliferative diseases.
Symbol: ALLK
Recent Price: $1.19
Industry: Biotechnology
CEO: Dr. Robert Alexander Ph.D.
Sector: Healthcare
Employees: 131
Address: 975 Island Drive, Redwood City, CA 94065
Phone: 650 597 5002
Leadership
- Robert Alexander, PhD, Chief Executive Officer
- Robert Andreatta, CFA, Vice President, Controller
- Neil Graham, MD, Chief Medical Officer
- Steven James, Biopharma Executive
- Amy Ladd, MD, Professor of Orthopaedic Surgery
- Dolca Thomas, MD, Venture Partner
- Paul Walker, CFA, Partner
Last updated: 2024-12-31
Fulcrum Therapeutics, Inc.
losmapimod and FTX-6058
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States.
Symbol: FULC
Recent Price: $4.68
Industry: Biotechnology
CEO: Mr. Alexander C. Sapir
Sector: Healthcare
Employees: 76
Address: 26 Landsdowne Street, Cambridge, MA 02139
Phone: 617 651 8851
Last updated: 2024-12-31
Kiromic BioPharma, Inc.
ALEXIS-ISO-1, ALEXIS-PRO-1
Kiromic Bio Pharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company that develops multi-indication T cell therapies, leveraging the Gamma Delta T cell to target solid tumors. Key products include ALEXIS-ISO-1 and ALEXIS-PRO-1.
Symbol: KRBP
Recent Price: $0.93
Industry: Biotechnology
CEO: Mr. Pietro Bersani CPA, J.D.
Sector: Healthcare
Employees: 35
Address: 7707 Fannin, Houston, TX 77054
Phone: 832 968 4888
Leadership
- Pietro Bersani, CPA, Director
- Leonardo Mirandola, PhD, Chief Scientific Officer/Interim COO
- Scott Dahlbeck, MD, PharmD, Chief of Staff
- Brian Hungerford, Chief Financial Officer
- Michael Nagel, Chairperson
- Michael Catlin, Independent Director
- Pam Misajon, Independent Director
Last updated: 2024-12-31
Protagonist Therapeutics, Inc.
rusfertide (PTG-300), PN-943, PN-235
Protagonist Therapeutics, Inc. is a biopharmaceutical company that focuses on the discovery and development of peptide-based therapeutic drugs for hematology, blood disorders, and inflammatory and immunomodulatory diseases.
Symbol: PTGX
Recent Price: $38.51
Industry: Biotechnology
CEO: Dr. Dinesh V. Patel Ph.D.
Sector: Healthcare
Employees: 125
Address: 7707 Gateway Boulevard, Newark, CA 94560-1160
Phone: 510 474 0170
Last updated: 2024-12-31
Omeros Corporation
Narsoplimab
Omeros Corporation is a commercial-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for inflammation, immune-related cancers, and addictive disorders.
Symbol: OMER
Recent Price: $9.74
Industry: Biotechnology
CEO: Dr. Gregory A. Demopulos M.D.
Sector: Healthcare
Employees: 198
Address: The Omeros Building, Seattle, WA 98119
Phone: 206 676 5000
Last updated: 2024-12-31
Aclaris Therapeutics, Inc.
Zunsemetinib
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune-inflammatory diseases. It operates through Therapeutics and Contract Research segments, addressing unmet needs with innovative therapies, including treatments for rheumatoid and psoriatic arthritis, atopic dermatitis, autoimmune diseases, inflammatory bowel disease, and certain cancers.
Contact | Careers | About | About | Directors | Leadership | About | Careers | About | About | Jobs
Symbol: ACRS
Recent Price: $2.48
Industry: Medical - Diagnostics & Research
CEO: Dr. Neal S. Walker D.O., M.D.
Sector: Healthcare
Employees: 86
Address: 640 Lee Road, Wayne, PA 19087
Phone: 484 324 7933
Last updated: 2024-12-31
Altimmune, Inc.
Pemvidutide
Altimmune, Inc. focuses on developing treatments for obesity and liver diseases with lead product candidate pemvidutide, and Hep Tcell in clinical trials.
Symbol: ALT
Recent Price: $7.32
Industry: Biotechnology
CEO: Dr. Vipin K. Garg Ph.D.
Sector: Healthcare
Employees: 59
Address: 910 Clopper Road, Gaithersburg, MD 20878
Phone: 240 654 1450
Last updated: 2024-12-31
89bio, Inc.
pegozafermin
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.
Symbol: ETNB
Recent Price: $7.87
Industry: Biotechnology
CEO: Mr. Rohan Palekar
Sector: Healthcare
Employees: 70
Address: 142 Sansome Street, San Francisco, CA 94104
Phone: 415 432 9270
Last updated: 2024-12-31
Galectin Therapeutics Inc.
belapectin (GR-MD-02)
Galectin Therapeutics Inc. engages in research and development of therapies for fibrotic, cancer, and other diseases, with a focus on developing galectin-3 inhibitors like belapectin.
Symbol: GALT
Recent Price: $1.10
Industry: Biotechnology
CEO: Mr. Joel Lewis
Sector: Healthcare
Employees: 14
Address: 4960 Peachtree Industrial Boulevard, Norcross, GA 30071
Phone: 678 620 3186
Last updated: 2024-12-31
GlycoMimetics, Inc.
uproleselan
Glyco Mimetics, Inc. is a clinical-stage biotechnology company that focuses on discovering and developing novel glycomimetic drugs to address unmet medical needs related to diseases, currently developing treatments for conditions such as acute myeloid leukemia and cancers affecting bone and bone marrow.
Symbol: GLYC
Recent Price: $0.25
Industry: Biotechnology
CEO: Mr. Harout Semerjian
Sector: Healthcare
Employees: 35
Address: 9708 Medical Center Drive, Rockville, MD 20850
Phone: 240 243 1201
Last updated: 2024-12-31
Immunic, Inc.
IMU-838
Immunic, Inc. develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, in Phase 2 clinical trials for multiple conditions, including relapsing-remitting multiple sclerosis.
About | Vision/Values | Contact | Contact | Contact | Careers | About | About | About | About | About
Symbol: IMUX
Recent Price: $1.03
Industry: Biotechnology
CEO: Dr. Daniel Vitt Ph.D.
Sector: Healthcare
Employees: 85
Address: 1200 Avenue of the Americas, New York, NY 10036
Phone: 332 255 9818
Last updated: 2024-12-31
Incyte Corporation
JAKAFI, PEMAZYRE, ICLUSIG
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.
About | Leadership | Contact | Contact | Locations | Contact | Contact | Culture | Jobs | Culture | DEI | News | Events | About | About | Careers | Jobs | Careers | Careers | DEI | Culture | Careers | Culture | DEI | Careers | Locations | Careers | About | About | About | About | About | Careers | About | About | Culture
Symbol: INCY
Recent Price: $68.42
Industry: Biotechnology
CEO: Mr. Herve Hoppenot
Sector: Healthcare
Employees: 2524
Address: 1801 Augustine Cut-Off, Wilmington, DE 19803
Phone: 302 498 6700
Leadership
- Hervé Hoppenot, Chairman and Chief Executive Officer
- Paula J. Swain, Executive Vice President, Human Resources
- Pablo J. Cagnoni, M.D., President, Head of Research and Development
- Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
- Sheila A. Denton, J.D., Executive Vice President and General Counsel
- Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
- Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
- Denise Brashear, Vice President, Head of Global Communications
- Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
- Lee Heeson, Executive Vice President, Head of Incyte International
- Michael Morrissey, Executive Vice President and Head of Global Technical Operations
- Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
- Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
- Julian C. Baker, Managing Partner
- Jean-Jacques Bienaime, Former Chief Executive Officer
- Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
- Paul J. Clancy, Former Executive Vice President and Senior Advisor
- Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
- Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
- Katherine High, M.D., Former President and Head of Research and Development
- Susanne Schaffert, Ph.D., Former President
Last updated: 2024-12-31
iTeos Therapeutics, Inc.
inupadenant, EOS-448
Iteos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics. Their product pipeline includes inupadenant and EOS-448, which are in various phases of clinical trials.
About | Leadership | Directors | About | About | About | About | Contact | Careers | About | About | About | About | About | About
Symbol: ITOS
Recent Price: $7.29
Industry: Biotechnology
CEO: Dr. Michel Detheux Ph.D.
Sector: Healthcare
Employees: 157
Address: 321 Arsenal Street, Cambridge, MA 02472-5710
Phone: 339 217 0161
Leadership
- Michel DETHEUX, President, Chief Executive Officer
- Matt CALL, Chief Operating Officer
- Matthew GALL, Chief Financial Officer
- Yvonne MCGRATH, Chief Scientific Officer
- David Feltquate, Chief Medical Officer
- Philippe BRANTEGEM, Executive Vice President of Human Resources
- Adi OSOVSKY, Executive Vice President of Legal
- David HALLAL, Chair of the Board
- Aaron DAVIS,
- Jill DESIMONE,
- David LEE,
- Tim VAN HAUWERMEIREN,
- Tony HO,
- Robert IANNONE,
- Ann RHOADS,
Last updated: 2024-12-31
Phio Pharmaceuticals Corp.
INTASYL therapeutic platform
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.
Symbol: PHIO
Recent Price: $1.90
Industry: Biotechnology
CEO: Mr. Robert J. Bitterman
Sector: Healthcare
Employees: 8
Address: 257 Simarano Drive, Marlborough, MA 01752
Phone: 508 767 3861
Last updated: 2024-12-31
Regulus Therapeutics Inc.
RG-012 and RGLS8429
Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.
Symbol: RGLS
Recent Price: $1.50
Industry: Biotechnology
CEO: Mr. Joseph P. Hagan M.B.A.
Sector: Healthcare
Employees: 30
Address: 4224 Campus Point Court, San Diego, CA 92121
Phone: 858 202 6300
Last updated: 2024-12-31
Acelyrin, Inc.
izokibep
Acelyrin, Inc. is a clinical biopharma company focused on developing and commercializing transformative medicines, with key products targeting conditions like Hidradenitis Suppurativa and Psoriatic Arthritis.
Symbol: SLRN
Recent Price: $3.08
Industry: Biotechnology
CEO: Ms. Mina Kim
Sector: Healthcare
Employees: 93
Address: 4149 Liberty Canyon Road, Agoura Hills, CA 91301
Phone: 805-730-0360
Last updated: 2024-12-31
Synlogic, Inc.
Synthetic Biotic Medicines
Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on the development of synthetic biotic medicines to treat metabolic and immunological diseases. The company's pipeline includes drug candidates for conditions such as phenylketonuria, homocystinuria, enteric hyperoxaluria, and solid tumors and lymphoma.
Symbol: SYBX
Recent Price: $1.40
Industry: Biotechnology
CEO: Mr. Antoine Awad
Sector: Healthcare
Employees: 6
Address: 301 Binney Street, Cambridge, MA 02142
Phone: 617 401 9975
Last updated: 2024-12-31
TG Therapeutics, Inc.
Ublituximab, Umbralisib, Cosibelimab, TG-1701, TG-1801
TG Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.
About | About | Leadership | About | About | About | About | Our Story | Contact | Contact | About | About
Symbol: TGTX
Recent Price: $31.45
Industry: Biotechnology
CEO: Mr. Michael S. Weiss Esq.
Sector: Healthcare
Employees: 264
Address: 2 Gansevoort Street, New York, NY 10014
Phone: 212 554 4484
Leadership
- Michael S. Weiss, Chairman, President, and Chief Executive Officer
- Sean A. Power, CPA, Chief Financial Officer
- Adam Waldman, Chief Commercialization Officer
Last updated: 2024-12-31
UroGen Pharma Ltd.
RTGel and Jelmyto
Uro Gen Pharma Ltd. develops and commercializes novel solutions for specialty cancers and urothelial diseases, with products like RTGel and Jelmyto and a focus on non-muscle invasive urothelial cancer treatments.
Symbol: URGN
Recent Price: $10.52
Industry: Biotechnology
CEO: Ms. Elizabeth A. Barrett
Sector: Healthcare
Employees: 203
Address: 400 Alexander Park, Princeton, NJ 08540
Phone: 646 768 9780
Last updated: 2024-12-31
Seelos Therapeutics, Inc.
SLS-002, SLS-005, SLS-006, SLS-007, SLS-008, SLS-004, SLS-010
Seelos Therapeutics, Inc. is focused on developing and commercializing therapeutics for central nervous system, respiratory, and other disorders, with lead programs targeting major depressive disorders, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Parkinson's disease.
Symbol: SEEL
Recent Price: $0.37
Industry: Biotechnology
CEO: Dr. Raj Mehra J.D., Ph.D.
Sector: Healthcare
Employees: 8
Address: 300 Park Avenue, New York, NY 10022
Phone: 646 293 2100
Last updated: 2024-12-31